[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Helwan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":283},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,61,88,122,142,170,192,210,234,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100641224","phase-4-continuous-infusion-versus-intermittent-iv-bolus-of-cefazolin-prevention-of-surgical-site-infection-during-orthopedic-surgeries-in-egyptian-patients-100641224",false,"NCT07655596","Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During Orthopedic Surgeries in Egyptian Patients.","Inclusion Criteria:\n\n* Orthopaedic surgical ward patients who underwent major surgery.\n\nExclusion Criteria:\n\n* Patients who require reoperation within 30 days.\n* Immunosuppressant patients.\n* Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","A randomized controlled trial on adults who underwent orthopedic surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population.\n\nEligible patients will be randomized in a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).",[25],"Surgical Site Infection (SSI)",[27,28],"cefazolin","orthopedic surgery","NOT_YET_RECRUITING","2026-06-19",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":19},"2026-07-01",{"date":37,"type":19},"2026-12-31",{"name":39,"class":40},"Helwan University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":4},"100641172","phase-4-continuous-infusion-versus-intermittent-iv-bolus-of-cefazolin-prevention-of-surgical-site-infection-during-cabg-surgeries-in-egyptian-patients-100641172","NCT07658378","Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.","Inclusion Criteria:\n\n* Cardiothoracic ICU-admitted patients who underwent CABG on CPB.\n\nExclusion Criteria:\n\n* Patients who require reoperation within 30 days.\n* Immunosuppressant patients.\n* Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.\n* Pregnancy or breastfeeding.\n* Patients who refused to sign the informed consent.",{"count":18,"type":19},[22],"A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.\n\nEligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).",[25],[27,52,53,54,55,56],"continuous infusion","intermittent","surgical site infection","surgical prophylaxis","CABG",{"date":32,"type":33},{"date":35,"type":19},{"date":37,"type":19},{"name":39,"class":40},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":20,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100643948","phase-3-colistin-nephrotoxicity-and-role-of-alpha-lipoic-acid-100643948","NCT07668141","Colistin Nephrotoxicity and Role of Alpha Lipoic Acid","Colistin Nephrotoxicity in Hospitalized Patients: The Role of Biomarkers in Guiding the Preventive Strategies","Inclusion Criteria:\n\n* Adult patients who receive intravenous colistin and had positive cultures of multidrug resistant gram negative bacteria.\n* Patients who receive colistin for at least 3 days during their treatment.\n\nExclusion Criteria:\n\n* Patients who receive inhaled colistin.\n* Patients who had AKI at baseline\n* chronic kidney disease patients on regular hemodialysis.\n* Renal transplant patients\n* Concurrent use of other nephrotoxic drugs e.g. vancomycin, gentamicin, amikacin and amphotericin B.\n* Concurrent use of other antioxidants e.g. vitamin C, vitamin E and N-acetyl cysteine.\n* Patients are not willing to participate in the study.\n* Patients with any missed doses of colistin and or alpha-lipoic acid.\n* Patients with incomplete medical data\n* Pregnant or breastfeeding women.","80 Years",{"count":70,"type":19},88,[72],"PHASE3","Nephrotoxicity is a great concern in patients receiving intravenous colistin and there is a disparity in the reported rates between previous studies. Several preclinical researches studied the effect of the antioxidants (e.g. L.carnitine, vitamin C, vitamin E, N-acetyl cysteine, and alpha lipoic acid) in reducing the risk of colistin-induced nephrotoxicity but there is a lack of clinical studies on human. Due to the paucity of studies that early predict colistin-induced nephrotoxicity using early acute kidney injury \"AKI\" biomarkers e.g. kidney injury molecule 1\"KIM1\" and the lack of human studies that evaluate the role of alpha lipoic acid in ameliorating colistin-induced nephrotoxicity, so this study will be conducted.",[75],"Nephrotoxicity",[77,78,79,75],"colistin","Alpa lipoic acid","kidney injury molecule-1",{"date":81,"type":33},"2026-06-25",{"date":83,"type":19},"2026-06-30",{"date":85,"type":19},"2027-02-28",{"name":39,"class":40},2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":20,"phases":97,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":87},"100633704","phase-3-comparative-efficacy-and-safety-of-propofol-ketamine-combination-versus-propofol-monotherapy-in-geriatric-patients-under-invasive-ventilation-100633704","NCT07530146","Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Admitted to ICU with a diagnosis of infection (sepsis, septic shock, or pneumonia)\n* Known history of cardiac disease (e.g., ischemic heart disease, heart failure, arrhythmias)\n* Requiring endotracheal intubation for airway protection or respiratory failure\n* Informed consent obtained from patient or legal representative\n* Patient NOT on sedation prior randomization.\n\nExclusion Criteria:\n\n* Known allergy or contraindication to propofol or ketamine\n* Severe hepatic or renal dysfunction (Child-Pugh C, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Uncontrolled hypertension (SBP \\> 180 mmHg or DBP \\> 110 mmHg)\n* Intracranial pathology (e.g., raised intracranial pressure, recent stroke, brain tumor)\n* Ongoing use of other sedative or anesthetic agents within 12 hours prior to intubation\n* Do-not-intubate or do-not-resuscitate orders\n* Participation in another interventional trial within the last 30 days\n* History of Psychosis\n* Severe Organ Dysfunction: Patients with Child-Pugh C hepatic failure\n* • Severe hypotension despite vasopressor therapy (systolic blood pressure \\\u003C 100 mmHg or diastolic blood pressure \\\u003C 70 mmHg)","65 Years",{"count":96,"type":19},41,[72],"The study is a prospective randomized controlled trial comparing the efficacy and safety of propofol-ketamine (\"Ketofol\") versus propofol monotherapy in geriatric ICU patients. Eligible participants are critically ill elderly patients with a history of cardiac disease who require endotracheal intubation and have not yet received sedation. The investigators focus on a specific population in which geriatric patients have different pharmacokinetics and pharmacodynamics and are more prone to side effects than other populations.\n\nPrimary outcome: Incidence of hemodynamic instability (defined as hypotension requiring vasopressors), measured by mean arterial pressure (MAP) at baseline, during intubation, and post-intubation at 1, 3, 5, 10, 20, 30, and 60 minutes, then hourly for 24 hours.",[100,101,102],"The Critically Ill Patient is Requiring Intubation","Septic Shock","Pneumonia",[104,105,106,107,108,109,110,111,112],"ketofol","propofol","septic shock","pneumonia","geriatric","elderly","critical ill","ICU patient","intubation","RECRUITING","2026-05-28",{"date":116,"type":33},"2026-06-01",{"date":118,"type":19},"2026-04",{"date":120,"type":19},"2026-10",{"name":39,"class":40},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100635172","model-informed-precision-dosing-of-tacrolimus-in-pediatric-kidney-transplantation-100635172","NCT07549230","Model-Informed Precision Dosing of Tacrolimus in Pediatric Kidney Transplantation","Model-Informed Precision Dosing of Tacrolimus in Pediatric Kidney Transplantation: A Hybrid Population Pharmacokinetics-Machine Learning Approach","Inclusion Criteria:\n\n* Pediatric patients (\\\u003C 18 years old).\n* First-time kidney transplant recipients who have less than 20% PRA and no DSA.\n* Adherent to tacrolimus for a year post-transplantation.\n* All data, including therapeutic drug monitoring (TDM) data, are available.\n\nExclusion Criteria:\n\n* Non-adherent patients to tacrolimus.\n* Unavailable or missing data.",{"count":130,"type":19},130,"OBSERVATIONAL","The purpose of this study is to develop a novel and applicable dosing algorithm that helps support the clinical decision to achieve tacrolimus levels within the optimal immunosuppression range despite sparse sampling in routine clinical practice in pediatric kidney transplantation. This clinical decision support tool (CDST) is based on a hybrid population pharmacokinetics-machine learning approach aiming for tacrolimus dose individualization and reducing the risk of acute graft rejection.",[134],"Pediatric Kidney Transplantation","2026-04-23",{"date":137,"type":33},"2026-04-29",{"date":116,"type":19},{"date":140,"type":19},"2027-06-01",{"name":39,"class":40},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":20,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100619264","using-retrograde-intrarenal-surgery-for-managing-staghorn-renal-stones-100619264","NCT07342361","Using Retrograde Intrarenal Surgery for Managing Staghorn Renal Stones.","Using Bendable Tip-suction Ureteral Access Sheath Compared to Conventional Sheath in Managing Renal Staghorn Stones A Randomized Prospective Study","Inclusion Criteria:\n\n* Adult patients of both sexes.\n* Patient has a staghorn renal stone (complete or partial staghorn).\n* Normal renal function tests.\n* Congenital renal anomalies as horseshoe, pelvic or mal-rotated kidneys.\n\nExclusion Criteria:\n\n* Abnormal coagulation profile.\n* Active or untreated urinary tract infection.\n* Age under 18 years or above 70 years.\n* Patient has a staghorn stone associated with other pathology which requires additional intervention, as ureteral stricture or ureteropelvic junction obstruction (UPJO).\n* Pregnancy.","70 Years",{"count":18,"type":19},[152],"NA","This prospective, randomized study is comparing the safety and efficacy of using two types of ureteral access sheaths in managing staghorn renal stones by retrograde intrarenal surgery.",[155],"Renal Calculi",[157,158,159,160],"staghorn calculi","retrograde intrarenal surgery","Ureteral access sheath","Suction","2026-01-30",{"date":163,"type":33},"2026-02-03",{"date":165,"type":33},"2026-01-20",{"date":167,"type":19},"2026-12-01",{"name":39,"class":40},1,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":20,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":169},"100553868","phase-4-cardiotoxicity-in-breast-cancer-patients-100553868","NCT06491680","Cardiotoxicity in Breast Cancer Patients","Evaluation of the Cardioprotective Effect of Dapagliflozin on Anthracyclines-Induced Cardiotoxicity in Breast Cancer Patients","Inclusion Criteria:\n\n1. patients with pathologically proved invasive breast carcinoma.\n2. Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines.\n3. Renal function (eGFR \\> 30 mL\u002Fminute per 1.73 m2 )\n4. LVEF is more than 50 %\n5. Age ≥ 18 and ≤ 60 years old\n\nExclusion Criteria:\n\n1. patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction.\n2. Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens\n3. pregnant or breastfeeding patients\n4. patients receiving any other cardiotoxic agents.\n5. Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.\n6. Mediastinal irradiation including heart.\n7. Refusal to sign the written informed consent.","60 Years",{"count":179,"type":19},40,[22],"The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.\n\nAim of the study:\n\nEvaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity.\n\nThe main questions it aims to answer are:\n\n1. Does the drug lower the cardiotoxicity which induced by anthracyclines?\n2. What medical problems do participants have when taking dapagliflozin drug?\n\nTreatment\n\n1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg\u002Fm2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg\u002Fm2 with cyclophosphamide 600 mg as a combination.\n2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.",[183],"Breast Cancer","2025-09-16",{"date":186,"type":33},"2025-09-22",{"date":188,"type":33},"2024-09-10",{"date":190,"type":19},"2026-06",{"name":39,"class":40},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":68,"enrollmentInfo":198,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":169},"100576531","a-direct-head-to-head-comparison-of-ustekinumab-with-infliximab-for-the-treatment-of-ulcerative-colitis-100576531","NCT06786507","A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","Inclusion Criteria:\n\n* Subjects who are voluntarily able to give informed consent\n* Subjects who can participate in all aspects of this clinical study\n* Males and females aged from ≥ 18 to ≤ 80 years, at screening visit\n* Diagnosis of moderate to severe UC established by clinical and endoscopic evidence.\n* Biological therapy naïve patients.\n\nExclusion Criteria:\n\n* \\- Previous exposure to IFX or UST or any other in IFX or UST-containing product\n* Has a history of hypersensitivity or allergies to the ingredients of IFX or UST formulations\n* Unstable angina\n* Moderate or severe heart failure (defined as New York Heart Association Class III or IV)\n* Chronic respiratory failure\n* History of any major neurological disorders including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease\n* Chronic hepatitis B or C infection. Patients with positive viral serology at screening for infection with hepatitis B (HBV) or hepatitis C virus (HCV) may be eligible if the polymerase chain reaction test is negative, and the patients receive standard of-care antiviral prophylaxis (if applicable)\n* Known severe chronic kidney failure\n* Known severe chronic liver failure\n* Known active or latent tuberculosis\n* Ongoing HIV infection",{"count":18,"type":19},"the goal of this study is to compare the efficacy of ustekinumab with infliximab for the treatment of ulcerative colitis aim of the study :\n\n1. Compare effectiveness of ustekinumab versus infliximab therapy in remission achievement in UC patients.\n2. Compare safety of ustekinumab therapy versus infliximab therapy in UC\n3. To asses quality of life of ustekinumab therapy versus infliximab therapy in UC patients.",[201],"Ulcerative Colitis (UC)","2025-01-15",{"date":204,"type":33},"2025-01-22",{"date":206,"type":19},"2025-05-15",{"date":208,"type":19},"2026-10-01",{"name":39,"class":40},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":20,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":169},"100549889","new-method-to-close-nasal-septal-perforation-100549889","NCT06439927","New Method to Close Nasal Septal Perforation","Nasal Septal Perforation Closure Using a 3-dimensional Fabricated Polycaprolactone Nasal Mesh","Inclusion Criteria:\n\n* Patients undergoing nasal septal perforation repair surgery.\n\nExclusion Criteria:\n\n* Patients with known allergy to polycaprolactone.\n* Pregnancy or lactation.","58 Years",{"count":219,"type":19},23,[152],"The goal of this clinical trial is to investigate if a 3-dimensional fabricated nasal mesh works to close nasal septal perforations. Under general anesthesia, during nasal septal perforation repair surgery, the investigator will place the mesh between the elevated mucoperichondrial flaps opposite the site of the perforation and confirm its original position at both sides under nasal endoscope. Endoscopic examination for septal mucosa status will be done monthly for a three months follow up period.",[223],"Nasal Perforated Septum",[225],"nasal septal perforation","2024-11-03",{"date":228,"type":33},"2024-11-05",{"date":230,"type":33},"2024-08-01",{"date":232,"type":19},"2025-12",{"name":39,"class":40},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":20,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":169},"100557239","phase-3-acetazolamide-versus-dapagliflozin-in-acute-decompensated-heart-failure-patients-100557239","NCT06535529","Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients","Inclusion Criteria:\n\n* Male or female patients of 18 years of age or older.\n* An elective or emergency hospital admission with clinical diagnosis of decompensated HF with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).\n* Assessed LVEF by any imaging technique; i.e. echocardiography, catheterization, nuclear scan magnetic resonance imaging within 12 months of inclusion.\n\nExclusion Criteria:\n\n* The receipt of acetazolamide maintenance therapy.\n* Receipt of an SGLT2 inhibitor in the 48 hours before randomization.\n* An estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2.\n* Use of any non-protocol defined diuretic agent with the exception of mineralocorticoid receptor antagonists during the treatment phase of the study. Thiazides, metolazone, indapamide and amiloride should be stopped upon study inclusion. If patient is taking a combination drug including a thiazide-type diuretic, the thiazide-type diuretic should be stopped.",{"count":241,"type":19},60,[72],"The goal of this clinical trial is to compare the effectiveness of acetazolamide versus dapagliflozin as an add-on in treating acute decompensated heart failure (ADHF) in adult patients with clinical signs of volume overload requiring intravenous loop diuretics. It will also assess the safety of these drugs when added to standard care. The main questions it aims to answer are:\n\n* Does acetazolamide or dapagliflozin lead to a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels?\n* Which drug results in better loop diuretic efficiency, as measured by weight loss per 40 mg of intravenous furosemide or equivalent? We will compare acetazolamide to dapagliflozin, both added to standard intravenous loop diuretic therapy, to see which is more effective in decongesting patients with ADHF.\n\nParticipants will:\n\n* Take either acetazolamide or dapagliflozin orally every day for 3 days\n* Receive intravenous loop diuretics as part of standard care\n* Undergo regular assessments of heart failure symptoms, weight, and laboratory tests\n* Be followed up until hospital discharge and for 30 days after starting the study",[245],"Acute Decompensated Heart Failure",[247,248,249,250,251],"Acute Heart failure","ADHF","Acetazolamide","SGLT2 inhibitors","SGLT2i",{"date":253,"type":33},"2024-08-05",{"date":255,"type":19},"2024-08-24",{"date":257,"type":19},"2025-09-01",{"name":39,"class":40},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":266,"minAge":16,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100542113","palbociclib-in-metastatic-breast-cancer-gene-polymorphism-based-study-in-egyptian-patients-100542113","NCT06338644","Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.","Palbociclib","Inclusion Criteria:\n\n* 1\\. Adult patients (≥18 years). 2. Confirmed diagnosis with MBC. 3. HR-positive\u002FHER2-negative MBC as ascertained by immunohistochemistry (IHC) or fluorescence in situ hybridization in primary or metastatic tissue samples.\n\n  4\\. Patients with primary or secondary resistance to endocrine therapy. 5. Patients with Eastern Cooperative Oncology Group (ECOG) 0 or 1. 6. Scheduled to receive Palbociclib in first- or second-line metastatic setting.\n\nExclusion Criteria:\n\n1. Prior exposure to fulvestrant or everolimus.\n2. Patients with uncontrolled brain metastases or symptomatic visceral spread who are at risk of life-threatening complications.\n3. Patients refusing to sign the written informed consent.","FEMALE",{"count":18,"type":19},"Cyclin-dependent kinase (CDK) 4\u002F6 inhibitors are a class of agents recently introduced in the clinic for the treatment of advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) BC. Palbociclib, ribociclib and abemaciclib have all been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency among other regulatory bodies",[270,271,272],"Hormone-receptor-positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Metastatic Breast Cancer",[274],"Metastatic breast Cancer, Palbociclib, Pharmacogenomic","2024-03-24",{"date":277,"type":33},"2024-03-29",{"date":279,"type":19},"2024-07-01",{"date":281,"type":19},"2026-09-01",{"name":39,"class":40},""]